ATE349468T1 - Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung - Google Patents

Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung

Info

Publication number
ATE349468T1
ATE349468T1 AT02737552T AT02737552T ATE349468T1 AT E349468 T1 ATE349468 T1 AT E349468T1 AT 02737552 T AT02737552 T AT 02737552T AT 02737552 T AT02737552 T AT 02737552T AT E349468 T1 ATE349468 T1 AT E349468T1
Authority
AT
Austria
Prior art keywords
deposit
epitope
forming polypeptide
multiple copies
antigenic peptide
Prior art date
Application number
AT02737552T
Other languages
English (en)
Inventor
Beka Solomon
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE349468T1 publication Critical patent/ATE349468T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/465—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02737552T 2001-06-20 2002-06-20 Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung ATE349468T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29920101P 2001-06-20 2001-06-20
US37171702P 2002-04-12 2002-04-12

Publications (1)

Publication Number Publication Date
ATE349468T1 true ATE349468T1 (de) 2007-01-15

Family

ID=26971089

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02737552T ATE349468T1 (de) 2001-06-20 2002-06-20 Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung

Country Status (10)

Country Link
US (1) US20050053575A1 (de)
EP (1) EP1397380B1 (de)
AT (1) ATE349468T1 (de)
AU (1) AU2002310474A1 (de)
CA (1) CA2450783A1 (de)
DE (1) DE60217107T2 (de)
DK (1) DK1397380T3 (de)
ES (1) ES2279869T3 (de)
PT (1) PT1397380E (de)
WO (1) WO2003000719A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2392247T3 (es) * 2002-03-05 2012-12-07 Ramot At Tel-Aviv University Ltd. Compuesto inmunizante y método para inducir una respuesta inmune contra el sitio de escisión de la beta-secretasa de la proteína precursora de amiloide
EP1911765A3 (de) * 2002-07-24 2008-04-23 Innogenetics N.V. Vorbeugung, Behandlung und Diagnose von Erkrankungen im Zusammenhang mit Beta-Amyloid-Bildung und/oder -Aggregation
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
EP1879613B1 (de) * 2005-05-05 2011-11-30 Merck Sharp & Dohme Corp. Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer-krankheit
EP1987361A4 (de) * 2006-01-30 2009-03-04 Invitrogen Corp Zusammensetzungen und verfahren zur erkennung und quantifizierung toxischer substanzen in krankheitsstadien
EP2201024A1 (de) 2007-08-28 2010-06-30 Ramot At Tel Aviv University Unter aufrechterhaltung einer vakanten cd4-bindungsstelle eine cd4i-konformation in hiv-gp120 induzierende peptide
WO2009079566A2 (en) * 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
US9241987B2 (en) 2009-11-20 2016-01-26 The University Of Chicago Methods and compositions related to immunogenic fibrils
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
CN103189050B (zh) 2010-10-26 2017-09-29 Ac免疫有限公司 包含通过疏水部分修饰的肽的基于脂质体的构建体
PL3505531T3 (pl) 2011-04-22 2024-03-11 Wyeth Llc Kompozycje związane ze zmutowaną toksyną Clostridium difficile i sposoby ich wytwarzania
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229490A (en) * 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
CA2172305A1 (en) * 1995-03-30 1996-10-01 Muneo Aoyama Multiple antigenic peptide comprising at least two hepatitis c virus-associated peptides
EP0861900A1 (de) * 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunologischer Nachweis von Prionen
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
DE19838751A1 (de) * 1998-08-26 2000-03-09 Hubert Kalbacher Verfahren zur Herstellung einer Affinitätsmatrix, Zwischenerzeugnis zur Herstellung und Anwendung der Affinitätsmatrix
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
CA2376619A1 (en) * 1999-06-29 2001-01-11 Dako A/S Detection using dendrimers bearing labels and probes

Also Published As

Publication number Publication date
WO2003000719A3 (en) 2003-12-11
CA2450783A1 (en) 2003-01-03
ES2279869T3 (es) 2007-09-01
US20050053575A1 (en) 2005-03-10
AU2002310474A1 (en) 2003-01-08
WO2003000719A2 (en) 2003-01-03
DK1397380T3 (da) 2007-05-07
EP1397380B1 (de) 2006-12-27
PT1397380E (pt) 2007-04-30
DE60217107T2 (de) 2007-08-23
DE60217107D1 (de) 2007-02-08
WO2003000719A8 (en) 2004-02-19
EP1397380A2 (de) 2004-03-17

Similar Documents

Publication Publication Date Title
ATE349468T1 (de) Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
TNSN06273A1 (en) Identification of self and non-self antigens implicated in autoimmune diseases
NO20053862L (no) Aktiv immunisering for a danne antistoffer mot loselig A-beta
NO963120L (no) Monoklonale antistoffer som binder til tumorrejeksjons-antigenforlöperen MAGE-3, rekombinant MAGE-1, og MAGE-1 avledete immunogene peptider
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
ATE269100T1 (de) Verfahren zur therapeutischen impfung
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
WO2003076455A3 (en) Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein
HK1093314A1 (en) Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
DE69716240D1 (de) Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten
DE69328726D1 (de) Verwendung synthetischer peptide zur induktion der toleranz gegen t- und b-zell epitope von autoantigenen
ATE453714T1 (de) Antigene aus cryptosporidium parvum, antikörper dagegen und diagnostische und therapeutische zusammensetzungen
TNSN08184A1 (en) Chimeric antigens and vaccines
MX2011004176A (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo.
DE60319350D1 (de) Gemeinsame epitope von antigenen aus einer multigen-familie
EP0972054A4 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
LT2002051A (en) Mimetic peptides for epitope of apoliprotein b-100, concatemer and modified peptides thereof, and the vaccine composition comprising the same
DE69626642T2 (de) Cetp zur erhöhung des hdl-cholesterol-gehalts
WO2002087611B1 (de) Mittel humanen ursprungs zur vakzination gegen gd2-positive tumore
ATE525470T1 (de) Antigene epitope des faktors viii, inhibitoren dagegen, und deren verwendungen
CR20240133A (es) Anticuerpos de transportador de monocarboxilato humano 1 y usos de estos
KR970074790A (ko) 합성 펩티드를 함유하는 녹농균 백신 및 이것으로부터 생산된 치료제
RU99100323A (ru) ВАКЦИНА, СОДЕРЖАЩАЯ ПЕРОКСИРЕДОКСИН И/ИЛИ β-ТУБУЛИН
Minassian et al. Efficacy of the novel Plasmodium falciparum blood-stage vaccine RH5. 1/AS01B in a phase I/IIA clinical trial

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1397380

Country of ref document: EP

REN Ceased due to non-payment of the annual fee